Clinical Trial Results: Tarceva [erlotinib]

Product Name: Tarceva [erlotinib]
Date of Report: 3/31/2004
Phase: III
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase III Study of Tarceva (Erlotinib) plus Chemotherapy (Cisplatin and Gemcitabine) Versus Chemotherapy Alone in Patients with Advanced (Stage IIIB or IV) Non–Small-Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Patients With Non–Small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non–Small Cell Lung Cancer (NSCLC)

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
A Study of Tarceva (Erlotinib) in Patients with Recurrent Glioblastoma Multiforme

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
MERIT study A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Dose-Finding Study of Tarceva (Erlotinib) in Combination Chemotherapy for Metastatic Colorectal Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Dose-Finding Study of Tarceva (Erlotinib) Given After Vinorelbine and Xeloda in Patients With Metatstatic Breast Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated With Tarceva (Erlotinib).

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: I
A Study of Tarceva (Erlotinib) in Combination With Alimta in Patients With Non-Small Cell Lung Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
MATER Study: A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer.